89例替米沙坦不良反应报告分析

中国药物警戒 ›› 2018, Vol. 15 ›› Issue (1): 49-51.

89例替米沙坦不良反应报告分析

韩宝侠¹, 曲虹^2,*, 苟小军²

1 苏州大学附属第二医院血透室,江苏苏州 215004;
2 上海市宝山区中西医结合医院药剂科,上海 201999;

收稿日期:2018-02-12 修回日期:2018-02-12 出版日期:2018-01-20 发布日期:2018-02-12
通讯作者: *曲虹,女,副主任药师,临床药学。E-mail：quhong6988@sina.com
作者简介:韩宝侠,女,主管护士,临床护理。
基金资助:
宝山区中西医结合医院院级基金（201610）：宝山区药品不良反应趋势分析

Analysis of 89 Cases of Adverse Reactions Induced by Telmisartan

HAN Bao-xia¹, QU Hong², GOU Xiao-jun²

1 Blood Room of Second Affiliated Hospital of Soochow University, Jiangsu Suzhou 215004, China;
2 Department of Pharmacy, Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine of Shanghai, Shanghai 201999, China;

Received:2018-02-12 Revised:2018-02-12 Online:2018-01-20 Published:2018-02-12

摘要/Abstract

摘要： 目的探讨替米沙坦药品不良反应（ADR）的一般规律和特点,为临床合理用药提供参考。方法从我区药品不良反应监测中心药品不良反应监测管理系统中调取2014年1月至2016年12月填报的替米沙坦相关ADR报告共89例,通过回顾性统计法对ADR报告进行综合分析。结果 89例ADR患者中,女性发生率高于男性,年龄集中在61~70岁（40.45％）;主要累及系统-器官为消化系统（44.92％）和皮肤及其附件（25.84％）,主要临床表现为恶心、呕吐、腹痛、腹泻、湿疹、瘙痒、生殖器红肿、生殖器瘙痒、嘴唇红肿、面部水肿、眼睑水肿等;ADR多在用药后2 d内发生（53.93％）。结论替米沙坦具有良好的安全性和耐受性,临床应用过程中加强用药监测,减少ADR发生,确保用药安全。

关键词: 替米沙坦, 不良反应, 监测, 分析

Abstract: Objective To explore the general regulation and characteristics of adverse drug reactions(ADR) induced by telmisartan, and provide reference for clinical rational drug use. Methods 89 cases of telmisartan related ADR were extracted from the adverse drug reaction monitoring and management system for drug adverse reactions in our district from January 2014 to December 2016, and comprehensively analyzed by retrospective classified statistics. Results Among the 89 ADR patients, the incidence of female was higher than that of male, and the age mainly distributed in the range of 61 to 70 years old (40.45％). The mainly involved organs/systems were digestive system (44.92%) and skin and its accessories (25.84%), the main clinical manifestations were nausea, vomiting, abdominal pain, diarrhea, eczema, itching, genital swelling, genital itching, lips swelling, facial edema, eyelid edema, etc. Conclusion Telmisartan has good safety and tolerability, enhance medication monitoring, and reduce ADR occurrence in order to ensure drug safety during clinical application.

Key words: telmisartan, adverse reactions, monitoring, analysis

中图分类号:

R994.11

韩宝侠, 曲虹, 苟小军. 89例替米沙坦不良反应报告分析[J]. 中国药物警戒, 2018, 15(1): 49-51.

HAN Bao-xia, QU Hong, GOU Xiao-jun. Analysis of 89 Cases of Adverse Reactions Induced by Telmisartan[J]. Chinese Journal of Pharmacovigilance, 2018, 15(1): 49-51.

参考文献

[1] 范秀珍,郭敌,王华杰.氨氯地平与其联合替米沙坦治疗轻中度高血压的对照研究[J].现代医学,2012,40(1):35.
[2] 唐新明. 离退休干部药物不良反应41例调查分折[J], 海军医学杂志,2012,33(6):403-404.
[3] 赵晓云,路永刚,赵海利,等. 河北省51239体检人群高血压流行病学分析[J].中国老年医学,2013,33(19):4818-4820.
[4] 李军象,颜永平. 替米沙坦联合小剂量吲达帕胺治疗老年原发性高血压的疗效观察[J].中国社区医师,2017,33(6):18-19.
[5] 江彦,傅彦妍,宋洪涛. 我院105例多西紫杉醇不良反应报告分析[J].中国药房,2016,27(26):3646-3649.
[6] 张歆, 秦文明, 翟淑越. 137 例甘露醇注射液不良反应分析[J].中国药物警戒,2016,13(6):364-366.
[7] 龚珊珊,王金明. 国内替米沙坦不良反应文献分析[J]. 药物流行病学杂志,2010,19(6):354-356.
[8] 唐福全. 口服卡托普利致高血钾1例报告[J].锦州医学院学报,2005,26(3):56.
[9] Michel M C,Bohncr H,Koster J,et a1.Safety of telrnisartan in Patients with arterial hypertension:an open-label observational study[J].Drug Saf,2004,27(5):335-344.
[10] 柏瑾,诸骏仁,蔡绳,等.替米沙坦治疗轻中度高血压的临床疗效和安全性-多中心随机对照临床试验[J].中华心血管病杂志,2002,30(12):738-742.
[11] 黄鹤宇,付军. 替米沙坦降压疗效相关单核苷酸多态性的研究进展[J]. 中国老年学杂志,2013,33(1):234-236.
[12] 卫生部.药品不良反应报告和监测管理办法[S/OL].(2011-05-04)[2017-08-01].http://www.sda.gov.cn/WS01/CL0053/62621.html.
[13] 杨华,魏晶,王嘉仡,等. 药品不良反应/事件报告评价方法研究[J]. 中国药物警戒,2009,6(10):581-584.
[14] 陈芳莲,农秋林.苯磺酸左旋氨氯地平片治疗高血压的临床疗效分析[J].临床合理用药杂志,2014,7(11):26-27.
[15] 向春, 汪潭,张顺利. 替米沙坦联合吲达帕胺治疗老年原发性高血压的临床效果探讨[J]. 中外医学研究,2017,15(18):125-126.